#CD4

NIH-funded study suggests need to boost CD8+ T cell response after infection.

More than a quarter of HIV-positive people with a CD4 count below 100 died from mpox complications.

After 52 weeks, 83% had an undetectable viral load.

Overall, people with and without HIV had low and comparable rates of severe breakthrough illness.

People with suppressed HIV respond well to mRNA vaccines, but individuals with a low CD4 count may not be adequately protected.

Customized T-cell treatment is generally safe for people living with HIV, and outcomes are comparable to those of HIV-negative people.

The long-acting HIV capsid inhibitor worked well for harder-to-treat groups, such as those with a low CD4 count.

However, lung cancer incidence among HIV-positive people has fallen over the past two decades.

People with well-controlled HIV don’t have more severe illness, but HIV-positive people might not respond as well to monkeypox vaccines.

People with HIV who start treatment before their CD4 T-cell count falls below 800 have a substantially smaller viral reservoir.

People who saw substantial CD4 T-cell gains during the first two years after diagnosis had better outcomes.

Having HIV can speed up the aging process by up to five years, underlining the importance of early diagnosis and treatment.

The study findings underscore the importance of starting antiretroviral therapy as soon as possible.

After advances in HIV therapy, long-acting antiretrovirals and long-term remission are the next frontiers.